Recent results obtained using molecular biology techniques have suggested a possible role for insulin‐like growth factor II (IGF‐II) in the pathogenesis of hepatocellular carcinoma (HCC). To investigate this phenomenon, a monoclonal anti‐body was used against IGF‐II to study 54 patients with HCC. The presence of HBsAg was also tested both in serum and liver tissue. A positive immunoreaction was found in 9/15 (60%) of the HCC arising in cirrhotic livers of patients who had serum markers for HBV (HBV+ positive patients). These results provide further evidence that HBV might play a role in the expression of IGF‐II. In HCC of patients without any markers of HBV infection (HBV‐ negative patients), IGF–II was detected in 10/39 (25.6%) of the tumors, and in some benign neoplastic lesions. It was found not only in neoplastic cells but also in some dysplastic nodules. The speculation arises that IGF–II expression may play a role in some steps of hepato‐carcinogenesis. Copyright © 1994, Wiley Blackwell. All rights reserved
D'Errico A., Grigioni W.F., Fiorentino M., Baccarinl P., Lamas E., Mitri S.D., et al. (1994). Expression of insulin‐like growth factor II (IGF–II) in human hepatocellular carcinomas: An immunohistochemical study. PATHOLOGY INTERNATIONAL, 44(2), 131-137 [10.1111/j.1440-1827.1994.tb01697.x].
Expression of insulin‐like growth factor II (IGF–II) in human hepatocellular carcinomas: An immunohistochemical study
D'Errico A.;Grigioni W. F.;Fiorentino M.;Gozzetti G.;Mancini A. M.;
1994
Abstract
Recent results obtained using molecular biology techniques have suggested a possible role for insulin‐like growth factor II (IGF‐II) in the pathogenesis of hepatocellular carcinoma (HCC). To investigate this phenomenon, a monoclonal anti‐body was used against IGF‐II to study 54 patients with HCC. The presence of HBsAg was also tested both in serum and liver tissue. A positive immunoreaction was found in 9/15 (60%) of the HCC arising in cirrhotic livers of patients who had serum markers for HBV (HBV+ positive patients). These results provide further evidence that HBV might play a role in the expression of IGF‐II. In HCC of patients without any markers of HBV infection (HBV‐ negative patients), IGF–II was detected in 10/39 (25.6%) of the tumors, and in some benign neoplastic lesions. It was found not only in neoplastic cells but also in some dysplastic nodules. The speculation arises that IGF–II expression may play a role in some steps of hepato‐carcinogenesis. Copyright © 1994, Wiley Blackwell. All rights reservedI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
